Zacharon Pharmaceuticals, Inc. is a biotechnology company founded on opportunities to discover first-in-class small molecule drugs that target glycans. Glycans, the carbohydrate chains of glycoproteins, proteoglycans, and glycolipids, represent a relatively unexploited area for drug development.

Past attempts at developing drugs that target glycans have been limited by slow and expensive carbohydrate chemistry as well as the lack of effective glycan-targeted high-throughput screening methods. Zacharon has created novel high-throughput screening methods to overcome these limitations and identify glycan-targeted small molecule drugs with strong efficacy and safety profiles.  With our technology and glycobiology expertise, Zacharon has the opportunity to dominate the field of glycan-targeted drug discovery.

The assay technology developed by Zacharon has potential beyond the company’s own internal development programs. This technology has the potential to enhance drug development and guide clinical decision-making for diseases in which glycans are implicated in disease pathogenesis.